Santhera Pharmaceuticals Holding AG Logo

Santhera Pharmaceuticals Holding AG

Develops innovative medicines for rare neuromuscular and mitochondrial disorders.

SANN | SW

Overview

Corporate Details

ISIN(s):
CH1276028821
LEI:
54930035HAOFTTQH0U85
Country:
Switzerland
Address:
HOHENRAINSTRASSE 24, 4133 PRATTELN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of innovative medicines for patients with rare diseases. The company targets conditions with high unmet medical needs, primarily in the area of rare neuromuscular and mitochondrial disorders. Santhera's mission is to provide treatment options for diseases that severely impact the lives of affected children and adults and currently have limited or no available therapies. Its development efforts include advanced treatments such as gene therapy for conditions like LAMA2-deficient congenital muscular dystrophy (CMD).

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Santhera Pharmaceuticals Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Santhera Pharmaceuticals Holding AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Santhera Pharmaceuticals Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-01-11 N/A Non-Executive member Buy None 42,600.00 CHF
2022-01-10 N/A Executive member Buy None 14,420.00 CHF
2022-01-05 N/A Executive member Buy None 37,000.00 CHF

Peer Companies

Human Stem Cells Institute PJSC Logo
A biotech investor developing gene therapy, regenerative medicine, and genetic services.
Russian Federation
ISKJ
HUMASIS CO., LTD. Logo
Develops & manufactures rapid in-vitro diagnostic test kits & instruments for global POCT markets.
South Korea
205470
Humedix Co., Ltd. Logo
Develops hyaluronic acid-based pharma, aesthetics, medical devices, and offers CMO services.
South Korea
200670
HUONS CO., LTD. Logo
Global healthcare company providing pharmaceuticals, medical devices, and wellness products.
South Korea
243070
Huons Global Co., Ltd. Logo
Develops pharmaceuticals, medical devices, cosmetics, and health foods for the global market.
South Korea
084110
HWAIL PHARM. CO., LTD Logo
Develops and manufactures APIs, finished drugs, and functional ingredients for healthcare.
South Korea
061250
Hyloris Pharmaceuticals SA Logo
A biopharma company optimizing existing drugs for unmet needs via abbreviated pathways.
Belgium
HYL
HYUNDAI BIOLAND Co.,Ltd. Logo
Develops natural biomaterials for cosmetics, nutraceuticals, and regenerative medicine globally.
South Korea
052260
Icure Pharmaceutical Incorporation Logo
Develops transdermal patches for dementia/Parkinson's and offers cosmetic ODM/OBM services.
South Korea
175250

Talk to a Data Expert

Have a question? We'll get back to you promptly.